Overview: Colchicine tablets, capsules, and liquid are used to reduce complications from coronary artery disease, treat Familial Mediterranean Fever, and treat or prevent gout attacks. The most common ...

WASHINGTON — Colchicine does not protect against major cardiovascular adverse events after an acute myocardial infarction, according to a multinational placebo-controlled trial of more than 7000 ...

Colchicine does not significantly reduce perioperative atrial fibrillation (AF) or myocardial injury after non-cardiac surgery (MINS) in patients undergoing major non-cardiac thoracic surgery, ...

NEW YORK — New insights into colchicine's disruption of the pathway that contributes to arterial inflammation and new clinical studies of the drug could pave the way toward greater use of the ...

Please provide your email address to receive an email when new articles are posted on . Patients taking colchicine had a weighted hazard ratio of 0.82 (95% CI, 0.69-0.94) for cardiovascular events.

Against the sheer scale of morbidity and death due to the ongoing coronavirus disease 2019 (COVID-19) pandemic, the urgency of identifying drugs and other measures that reduce these adverse outcomes ...

AMSTERDAM -- Anti-inflammatory colchicine (Lodoco) given perioperatively around major non-cardiac thoracic surgery did not cut atrial fibrillation (Afib) or myocardial injury complications, the COP-AF ...

Please provide your email address to receive an email when new articles are posted on . In patients referred for PCI after acute heart attack, colchicine did not improve heart-related outcomes vs.

Taxpayer dollars spent on colchicine have spiked thanks to a regulatory quirk that enabled a company to exclusively market the centuries-old drug and allowed other manufacturers to follow suit. US ...